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Introduction 
 
This discussion paper aims to encourage Governments and other partners to take 
concerted action for the implementation of evidence-based drug dependence 
treatment services, which respond to the needs of their populations. Given the scale 
of the problem in most societies and the limited resources available, a clear and 
coherent approach to service planning is required. There is a need to develop 
services that can reach the maximum number of individuals and have the greatest 
impact at lowest cost. This is most likely to be achieved with broad community-based 
health care services that can work with individuals in their own communities over 
longer periods of time. While the present document recommends actions to promote 
each of the nine principles, these will need to be prioritized to respond to the local 
situation and circumstances and implemented in progressive steps in accordance 
with resource availability and stages of development of the treatment system.   
 
An estimated 205 million people in the world use illicit drugs, including 25 million who 
suffer from illicit drug dependence.  This constitutes a public health, socio-economic 
development and security problem for both industrialized and developing countries 
alike. The important role of drug dependence prevention and treatment as part of 
demand reduction and public health has been repeatedly emphasized in international 
agreements. The importance of maintaining an appropriate balance between law 
enforcement and demand reduction/public health approaches was most recently 
highlighted by the 1998 UNGASS Political Declaration and Declaration on the 
Guiding Principles of Drug Demand Reduction, bringing to the forefront a 
comprehensive approach in drug policy.  Further, in recent decades important 
advances have been made in the understanding of drug dependence and 
approaches for its prevention and treatment.  This joint UNODC-WHO document 
aims at articulating the key principles for underlying effective treatment of drug 
dependence.  
 
Drug dependence is considered a multi-factorial health disorder that often follows the 
course of a relapsing and remitting chronic disease. Unfortunately in many societies 
drug dependence is still not recognized as a health problem and many people 
suffering from it are stigmatized and have no access to treatment and rehabilitation.  
Over recent years, the biopsychosocial model has recognized drug dependence as a 
multifaceted problem requiring the expertise of many disciplines. A health sciences 
multidisciplinary approach can be applied to research, prevention and treatment.    
 
In the past decades, drug dependence has been considered, depending on the 
different beliefs or ideological points of view: only a social problem, only an 
educational or spiritual issue, only a guilty behavior to be punished, only a 
pharmacological problem. The notion that drug dependence could be considered a 
“self-acquired disease”, based on individual free choice leading to the first 
experimentation with illicit drugs, has contributed to stigma and discrimination 
associated with drug dependence. However, scientific evidence indicates that the 
development of the disease is a result of a complex multi-factorial interaction 
between repeated exposure to drugs, and biological and environmental factors.  
Attempts to treat and prevent drug use through tough penal sanctions for drug users 
fail because they do not take into account the neurological changes drug 
dependence has on motivation pathways in the brain. 
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 “Nothing less” must be provided for the treatment of drug dependence than a 
qualified,  systematic, science-based approach such as that developed to treat other 
chronic diseases considered untreatable some decades ago.  Many of  these 
diseases are now preventable or treatable thanks to good practice clinical 
interventions and rigorous therapeutic strategies and cumulative scientific research.  
 
Drug dependence and illicit drug use are associated with health problems, poverty, 
violence, criminal behavior, and social exclusion. Its total costs to society are difficult 
to estimate.  In addition to the health care costs and other costs associated with the 
consequences of drug use; drug dependence involves also social costs in the form of  
loss of productivity and family income, violence, security problems, traffic and 
workplace accidents, and links with corruption. These result in overwhelming 
economic costs and an unacceptable waste of human resources.  
 
Drug use, especially injecting drug use (IDU) is closely linked to HIV and hepatitis B 
and C transmission through the sharing of needles. Non injecting drug use is also 
linked to HIV transmission by increasing high risk sexual behaviors. Data on the size 
of the IDU population from 130 countries indicates that there are close to 10 million 
IDUs worldwide. Up to 10% of global HIV infections are due to unsafe injecting drug 
use, and if Sub-Saharan Africa is excluded, up to 30% of global HIV infections are 
due to unsafe injecting drug use. The sharing of contaminated injection equipment is 
a major route of HIV transmission in many regions, including Eastern Europe, 
Central, South and South East Asia and some countries in Latin America.  
 
Drug dependence is a preventable and treatable disease, and effective prevention 
and treatment interventions are available. The best results are achieved when a 
comprehensive multidisciplinary approach which includes diversified pharmacological 
and psychosocial interventions is available to respond to different needs. Even taking 
into account the requirements for the delivery of evidence–based treatment, its costs 
are much lower than the indirect costs caused by untreated drug dependence 
(prisons, unemployment, law enforcement, health consequences).  Research studies 
indicate that spending on treatment produces savings in terms of reduction in the 
number of crime victims, as well as reduced expenditures for the criminal justice 
system. At a minimum there was a 3:1 saving, and when a broader calculation of 
costs associated with crime, health and social productivity was taken into account, 
the rate of savings to investment rose to 13:1 . These savings can improve 
disadvantaged situations where opportunities for education, employment and social 
welfare are undermined, and increase possibilities for families to recover battered 
economies, thus facilitating social and economic development. Individuals involved in 
the criminal justice system may be at higher risk of health and social consequences 
of drug dependence. Drug taking behaviour inside the prison involves more harmful 
patterns leading to increased risk of contamination with infectious diseases like HIV 
and Hepatitis. The potential for imprisonment to cause harm should not be 
underestimated. 
 
A WHO / UNODC / UNAIDS policy brief on the reduction of HIV transmission through 
drug-dependence treatment recommended drug dependence treatment to be 
included in HIV/AIDS prevention programmes for injecting drug users given its 
capacity to reduce drug use in general, the frequency of injecting, and the levels of 
associated risk-taking behavior. Research has also shown that treatment in prisons 
or alternative measures to imprisonment can reduce post release use of drugs and 
re-offending. 
 
This paper outlines nine key principles for the development of services for treatment 
of drug use disorders. It is recognized that in some circumstances resources will be 
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 rather limited and priorities in resource allocation need to be set.  It is important that 
in such situations, a response to drug use disorders is developed as “building blocks” 
on which more diverse and sophisticated interventions can be developed and 
incorporated in the treatment system as further resources become available.  
Depending on human and financial resources available and the quality level of the 
existing health system in each country, the actions suggested by the present 
document may be progressively and gradually implemented, taking into account the 
outlined components for each principle as general framework. 
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 PRINCIPLE  1: AVAILABILITY AND ACCESSIBILITY OF DRUG DEPENDENCE 
TREATMENT  
 
Description and Justification  
Drug dependence and its associated social and health problems can be treated 
effectively in the majority of cases if people have access to continuum of available 
and affordable treatment and rehabilitation services in a timely manner. To this end, 
all barriers limiting accessibility to treatment services need to be minimized for people 
to have access to the treatment that best fits their needs. 
 
Components 
Many factors contribute to treatment accessibility:  
 Geographical accessibility, distribution and linkages.  
o Health care system and public health networks, in cooperation with social 
services and the broader community, can provide essential prevention and 
treatment services and support for people with drug use disorders in their 
communities. Social services and other institutions (e.g. schools, civil society 
organizations, and self help groups) can serve as points of first contact for 
potential patients and help them access treatment.  
o In a comprehensive treatment system a large scale, distributed network of 
treatment facilities that can respond to various needs of individuals seeking 
treatment permits an adequate response in each community.  
o The basic prevention and treatment services for drug use disorders need to 
be within the reach of people with different levels of income. 
o Within a continuum of care, people with drug dependence should have 
access to treatment services through multiple entry points. 
o Outreach services, as part of a continuum of care, are needed to reach the 
‘hidden’ populations most affected by drug use, often non-motivated to 
treatment or relapsing after a treatment program. Outreach services are 
particularly important to attract problematic drug users early and to establish 
contact with the population of people with severe disorders who may not seek 
treatment because of stigma and marginalization. 
 Timeliness and flexibility of opening hours. Same-day admission or short waiting 
time for structured services, as well as provision of immediate intermediate 
services, including patient information. A wide range of opening hours will 
facilitate access to services for individuals with employment or family 
responsibilities. 
 Legal framework. Requirements to register drug addicts in official records, if 
associated with the risk of sanctions, may discourage patients from attending 
treatment programmes, thus reducing accessibility. 
 Availability of low threshold services. Flexibility in the organization of treatment 
services will improve access by a larger range of individuals in need. This 
includes the availability of services with low threshold for patient admission and 
the removal of unnecessarily selective criteria.   
 Affordability. Payment for treatment and rehabilitation services may constitute a 
significant barrier for patients in many cases without sources of income. 
Insurance coverage or inclusion of drug dependence care in the public health 
care system is therefore key to promote access for those most in need. 
 Cultural relevance and user friendliness. Current knowledge indicates that a 
treatment climate that is culturally sensitive, preferably multi - professional, team 
orientated, and that encourages patient participation and involvement in 
treatment facilitates patient access and retention in treatment, and ultimately 
improved treatment outcomes. 
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  Responsiveness to multiple needs and diversification of settings. The availability 
of specialized services and residential settings to care for the more complex 
cases, e.g., patients with drug  dependence and associated somatic or 
psychiatric disorders is essential to increase accessibility. 
 Criminal justice system responses play a significant role in improving access for  
individuals affected by drug dependence to treatment services: law enforcement 
officials, courts and prisons may closely collaborate with the health system to 
encourage drug dependent individuals to enter treatment.  
 Gender-sensitiveness of services. Services tailored to gender-specific treatment 
needs can improve accessibility by responding to differential stigmatization, child 
care needs, and issues in pregnancy.  
 
Actions to promote this principle 
Ensure that: 
1. the system of services permeates both urban and rural areas, and builds upon 
the primary health care system. Key components include: proactive outreach, 
low-threshold, early identification and brief intervention in primary health and 
social care services, basic drug dependence treatment services, and referral to 
treatment services from the criminal justice system.   
2. legal frameworks guarantee protection from potential sanctions for those seeking 
treatment.  
3. there are functional referral and counter referral mechanisms between different 
services in the system as well as to and from other agencies, facilitating a 
continuum of care. 
4. the number of people on waiting lists and waiting times are minimized, and that 
intermediate responses are available. 
5. staff attitudes are welcoming and non-judgmental. 
6. services take into account and respect cultural norms. 
7. patients’ perspectives are taken into account in service design and development.  
8. eventual service costs to patients are affordable and waved if necessary. 
9. services for women in primary health care and facilities for children of parents 
with drug dependence are built in close relationship with drug dependence 
treatment programs. 
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 PRINCIPLE 2: SCREENING, ASSESSMENT, DIAGNOSIS AND TREATMENT PLANNING  
 
Description and Justification  
Patients affected by drug use disorders often have multiple treatment needs across a 
range of personal, social and economic areas that cannot be addressed when taking 
into consideration only their addictive symptoms in a standardized way. As for any 
other health care problems, diagnostic and comprehensive assessment processes 
are the basis for a personalized and effective approach to treatment planning and 
engaging the client into treatment. 
 
Components 
 Screening is a useful assessment procedure to identify individuals with 
hazardous or harmful drug use, or drug dependence, as well as associated risk 
behaviors (viral transmission via needle sharing and/or unprotected sexual 
activity, potential violent behavior, suicide risk).  There are standardized tools to 
assess drug use and its severity in an individual that help to consider the degree 
of help required.  These tools can be applied in different environments (primary 
health care system, school health and counselling services, and employee 
assistance programmes at work places).  
 Assessment and diagnosis are core requirements for treatment initiation. 
Diagnostic criteria commonly used in the mental health field are the references to 
reach a diagnosis of a drug use disorder. Diagnosis of co morbid psychiatric 
disorders is ideally made and followed-up by a psychiatrist, while with adequate 
training, other health care professionals can successfully identify and manage 
drug use disorders and associated psychiatric co-morbidity. 
 A comprehensive assessment takes into account the stage and severity of the 
disease, somatic and mental health status, individual temperament and 
personality traits, vocational and employment status, family and social 
integration, and legal situation. It further considers environmental and 
developmental factors, including childhood and adolescent history, family history 
and relationships, social and cultural circumstances, and previous treatment 
attendance. An adequate assessment process creates the environment for the 
development of a therapeutic alliance to engage the patient into treatment. 
 The treatment plan, developed with the patient, establishes goals based on the 
patient’s identified needs and sets interventions to meet those goals. A care or 
treatment plan is a written description of the treatment to be provided and its 
anticipated course. Care plans set the specific needs of the individual patient and 
how they are going to be met by the service. The plan is then monitored and 
revised periodically as required to respond to the patient’s changing situation. 
While current research results do not support matching patient profiles to specific 
treatment approaches, there is evidence that matching responses and 
interventions to client needs following a serious diagnostic process and extensive 
assessment improves the treatment outcomes. 
 
Actions to promote this principle 
Ensure that: 
1. primary health care staff, as well as employee assistance programmes and 
health/counseling staff in social services, at schools and in the criminal justice 
system are aware of the benefits of screening, early identification of drug use 
and brief interventions and are trained to administer such screening tools and 
associated interventions packages.  
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 2. patient risk behaviors associated with drug use disorders are assessed at all 
relevant venues (primary health care, outreach services, emergency services, 
social services, etc) and responses planned in consequence. 
3. accurate diagnosis of drug dependence and other co-morbid conditions is 
established before initiating drug dependence treatment, in particular 
pharmacological treatment.   
4. clinical protocols specify requirements for comprehensive patient assessment 
and the treatment plan development, patient progress monitoring and revision of 
written care plans, and relevant staff is trained to fulfil these tasks. 
5. documentation and standardization of all treatment steps is required from all 
staff involved in the treatment plan in order to ensure quality treatment for all 
patients 
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 PRINCIPLE 3: EVIDENCE-INFORMED DRUG DEPENDENCE TREATMENT  
 
Description and Justification  
Evidence-based good practice and accumulated scientific knowledge on the nature 
of drug dependence should guide interventions and investments in drug dependence 
treatment. The high quality of standards required for approval of pharmacological or 
psychosocial interventions in all the other medical disciplines should be applied to the 
field of drug dependence.  
 
Components 
 There is a range of evidence-based pharmacological and psychosocial 
interventions relevant to different stages in the addiction career and treatment 
process.  No single treatment is appropriate for all patients and differentiated and 
targeted treatment interventions respond best to the specific needs of each 
clinical condition. For example, moderate cases may be handled in primary care 
settings (e.g. general practitioners with relevant training), while more severely 
affected patients, especially those with co-morbidities, may require 
multidisciplinary interventions, including psychiatric evaluation and care. 
 Sufficient duration. In treating complex chronic diseases and preventing relapse, 
long-lasting treatment programmes have been found the most effective strategy 
and may be necessary in the more severe forms of drug dependence. It is 
therefore key for treatment services to develop approaches to facilitate long term 
patient retention in treatment. 
 The integration of psychosocial and pharmacological treatment methods can 
improve the outcome and should be proposed to the patients as part of a 
comprehensive approach. A holistic treatment orientation, treating the whole 
person, rather than the addiction only, has been shown to have better results in 
terms of relapse prevention.  
 Multidisciplinary teams including medical doctors, psychiatrists, psychologists, 
social workers, counsellors and nurses can respond best to needs of patients, 
also due to the multi-factorial nature of drug dependence. Treatment and care for 
physical conditions (liver disease, infections, pain etc) and concomitant 
psychiatric disorders utilizing both medications and psychosocial interventions 
may significantly improve the treatment outcomes. 
 Brief interventions. Individuals with experimental and occasional substance use 
can benefit from screening and brief interventions, which are an effective and 
economical prevention option, also at the early stages of substance use 
disorders. 
 Outreach and low-threshold interventions can reach patients not motivated to 
engage in structured forms of treatment.  These interventions offer a 
comprehensive package of measures to prevent the health and social 
consequences of drug dependence and have demonstrated effectiveness in 
preventing the transmission of HIV/AIDS and other blood-borne infections 
 Basic services offering the essential support to stop or reduce drug use need to 
be distributed and widely available thorough the territory, including detoxification, 
psychosocially assisted opioid agonist pharmacotherapy of opioid dependence, 
counselling, rehabilitation strategies and social support. 
 Medically supervised withdrawal is required for patients who are heavy 
dependent users of certain substances (such as opioids, sedative/hypnotic 
substances, and alcohol) and are likely to experience withdrawal 
complications. Detoxification is a preparatory step to start long lasting drug-free 
oriented programs. 
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  Maintenance medications with proven efficacy and effectiveness in preventing 
relapse and stabilizing drug dependent patients are available only for opioid 
dependence. These medications belong to two main groups: long-acting opioid 
agonists and antagonists. Opioid agonist pharmacotherapy is one of the most 
effective treatment options for opioid dependence when methadone or 
buprenorphine are administered at a individualized dosage for a period of several 
months to years. Alternatively, a defined group of opioid dependent patients who 
are detoxified and highly motivated can be prescribed an antagonist medication 
(naltrexone) as part of continuing relapse prevention treatment.    
 Psychological and social interventions have demonstrated to be effective in 
rehabilitation and relapse prevention, both in out-patient and residential settings.  
Psychotherapies such as cognitive behavioural therapy, motivational interviewing 
and contingency management, have shown promising results. Social support 
interventions like employment programmes, vocational training and legal advice 
and support have been demonstrated to be effective in facilitating social 
inclusion.  
 Self-help support groups complement formal treatment options and can support  
standardized psychosocial interventions  
 Socio-cultural relevance. Evidence-based treatment methodologies and 
strategies need to be adapted to the diverse regional, national and local 
circumstances, taking into account both cultural and economic factors.  
 Knowledge transfer and ongoing clinical research implemented in different 
settings and regions is key to permanently improve the treatment programs 
available to patients.   
 Training of treatment professionals from early on in their careers, including within 
university curricula and continuing education is essential to disseminate 
evidence-based methodologies.  
 
Actions to promote this principle  
Ensure that: 
1. available resources are invested in evidence-based interventions 
2. a comprehensive treatment system offers a wide range of evidence-based and 
integrated pharmacological and psychosocial interventions, aimed at treating 
the whole person.  The range includes interventions of diverse intensity, from 
outreach, low-threshold  and brief interventions to long-term, structured 
treatment 
3. the duration of treatment interventions is determined by individual needs, and 
there are no pre-set limits to the duration of treatment 
4. whenever possible, services are staffed by multidisciplinary teams adequately 
trained in the delivery of evidence-based interventions 
5. basic services including detoxification, psychosocially assisted opioid agonist 
maintenance pharmacotherapy for opioid dependence, counselling, and social 
support are available thorough the territory  
6. more complex cases, including patients with concomitant severe somatic and 
psychiatric disorders receive adequate care, possibly through referral to 
specialized services 
7. psychosocial interventions have demonstrated to be effective in rehabilitation 
and relapse prevention, both in out-patient and residential settings, in particular 
cognitive behavioural therapy, motivational interviewing and contingency 
management, employment and vocational training, counselling and legal advice. 
8. interventions are adapted for relevance to the socio-cultural environment in 
which they are applied, constantly updated in accordance to research 
developments and diversified research is conducted in all regions of the world. 
 
 
 9
 PRINCIPLE 4: DRUG DEPENDENCE TREATMENT, HUMAN RIGHTS, AND PATIENT 
DIGNITY  
 
Description and Justification  
Drug dependence treatment services should comply with human rights obligations 
and recognize the inherent dignity of all individuals.  This includes responding to the 
right to enjoy the highest attainable standard of health and well-being, and ensuring 
non-discrimination.  
 
Components 
 People with drug dependence should not be subject to discrimination because of 
their past of present drug use. 
 The same standards of ethical treatment should apply to the treatment of drug 
dependence as other health care conditions. These include the right to 
autonomy, and self determination on the part of the patient, and the obligation for 
beneficence and non-maleficence on behalf of treating staff.  
 Access to treatment and care services, including measures to prevent the health 
and social consequences of drug use, needs to be ensured in all the stages of 
the disease, also for the patients not motivated to stop drug use or relapsing after 
treatment, as well as during detention periods in prison. 
 As any other medical procedure, in general conditions drug dependence 
treatment, be it psychosocial or pharmacological, should not be forced on 
patients. Only in exceptional crisis situations of high risk to self or others, 
compulsory treatment should be mandated for specific conditions and periods of 
time as specified by the law.  
 When the use and possession of drugs results in state imposed penal sanctions, 
the offer of treatment as an alternative to imprisonment or other penal sanction 
presents a choice to the patient/offender, and although it entails a degree of 
coercion to treatment, the patient is entitled to reject treatment and choose the 
penal sanction instead. 
 Discrimination should not occur based on any grounds, be it gender, ethnic 
background, religion, political belief, or health, economic, legal or social 
condition.  
 The human rights of people with drug dependence should never be restricted on 
the grounds of treatment and rehabilitation. Inhumane or degrading practices and 
punishment should never be a part of treatment of drug dependence. 
 
Actions to promote this principle  
Ensure that: 
1. the legal framework guarantees compliance with human rights within drug 
dependence treatment and rehabilitation services. 
2. service procedures require staff to adequately inform patients of treatment 
processes and procedures, develop individual care plans jointly with the patient, 
obtain informed consent from the patient before initiating interventions, and 
guarantee the option to withdraw from treatment at any time.  
3. the privacy of patients is respected: patient data are strictly confidential and 
authorization from the patient in written form is requested before its use for any 
purposes.  
4. staff are properly trained in the provision of treatment in full compliance with 
ethical standards, and show respectful and non-stigmatizing attitudes.  
5. the provision of medical treatment services is not dependent on compliance with 
addiction treatment  
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 6. evidence-based prevention and treatment interventions for drug use disorders 
and associated health consequences are available also in prisons.  
7. for treatment research, ethical committees review and authorize research 
protocols, as is the case for all other medical disciplines.  
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 PRINCIPLE 5:  TARGETING SPECIAL SUBGROUPS AND CONDITIONS 
Description and Justification  
Several subgroups within the larger population of individuals affected by drug use 
disorders require special consideration and often specialized care.  These groups 
with specific needs include adolescents, women, pregnant women, people with 
medical and psychiatric co-morbidities, sex workers, ethnic minorities, and socially 
marginalized individuals. A person may belong to more than one of these groups and 
have multiple needs. 
 
The implementation of adequate strategies and provision of appropriate treatment for 
these patients often require targeted and differentiated approaches regarding 
contacting services and entering treatment, clinical interventions, treatment settings 
and service organization that respond best to the needs of these groups.  
 
Components   
 Adolescents: Ideally specialized training should be available for counsellors, 
outreach workers and other professionals involved in treatment of 
adolescents with drug use disorders, and child/adolescent psychiatrists and 
psychologists should be part of these multidisciplinary teams.   It may be 
counterproductive for young patients in early stages of drug use disorders to 
get in contact with people in more advanced stages of the disease through 
the treatment setting, and therefore, whenever possible, separate settings for 
adolescents and their parents can be considered. Planning and implementing 
interventions with young people will benefit from close cooperation with 
families and when appropriate, schools.  
 Women. Many treatment services and programs have been developed to 
meet the needs of adult men. . In most cultures women with drug problems 
are heavily stigmatized, though bearing large family care responsibilities.  As 
a result, access of women to treatment can be significantly limited.  In 
addition, women tend to have specific needs of their psychological status and 
psychiatric co-morbidity. Continued drug use affects their sexual and 
reproductive health.  Gender-responsive services are needed that consider 
the needs of women in all aspects of their design and delivery, including 
locations, staffing, programme development, child friendliness, content and 
materials. 
 Pregnant women.  In many cultures, approximately one third of people with 
drug dependence are women of childbearing age, so the possibility of 
pregnancies needs to be taken into account and optional pregnancy tests 
made available. Pregnancies in this population should always be considered 
as high risk.  This makes their treatment a specialized field, requiring a multi-
professional approach, including prenatal care. Evidence-based standards of 
pharmacotherapy for opioid dependence treatment during pregnancy are 
available. Breast-feeding should be supported if desired by the woman if no 
contraindication is present. This specialized care is as an opportunity to 
interact early on a case management basis to reduce additional risk factors.  
 People with medical co-morbidities (hepatitis B and C, HIV, TB, and 
cirrhosis).  People with drug dependence should be afforded the same level 
of access to treatment and care for medical co-morbidities as any other 
people in the country. For patients with opioid dependence, provision of 
agonist maintenance therapy can enhance adherence to treatment regiments 
for HIV, TB and hepatitis. Individual counselling, or with extended family 
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 members, if requested, is an important component of a comprehensive 
approach.  
 People with psychiatric co-morbidities: Research indicates a high prevalence 
of personality, affective and other psychiatric disorders among drug 
dependent patients.  It also shows that patient retention and treatment 
outcomes are related to the diagnosis and adequate treatment of these 
psychiatric co-morbidities.  In consequence, treatment services can improve 
their effectiveness by screening for associated psychiatric disorders and their 
adequate psychopharmacological treatment, taking into consideration 
possible drug-drug interactions.  
 Sex-workers: a significant proportion of drug dependent individuals are 
involved in sex work as a means to afford buying drugs. These individuals are 
exposed to increased risk of infections, victimization, violence and social 
exclusion. Interventions addressed to this specific group should prioritize 
outreach and offer a comprehensive package of measures to prevent HIV and 
hepatitis infection, and other sexually transmitted diseases. Sources of 
sustainable livelihood can be offered through social support and rehabilitation 
programmes. 
 Ethnic minorities may encounter particular barriers to access treatment 
services, including language difficulties.  These, as well as cultural and 
religious differences need to be taken into consideration when organizing 
treatment facilities. Cultural mediators may be involved in reaching these 
patients and helping them in attending treatment. 
 Marginalized/street people: A full package of social assistance and support in 
order to achieve means of sustainable livelihoods needs to be available to 
addicted patients living in the street, unemployed, homeless and rejected by 
their families. Dormitories, vouchers, free food, and temporary job 
opportunities offered in collaboration with social services in parallel with 
treatment services will support the patients’ stabilization. 
 
Actions to promote this principle 
Ensure that: 
1. treatment service provision and clinical protocols take into account the 
requirements of patients with special needs. 
2. patient assessments are comprehensive to enable broad medical and 
psychosocial interventions.  
3. integration of services or at least standardized procedures for referrals are 
established in order to provide continuity of care for patients with co-morbid 
conditions and  minimize the risk of losing a patient, also due to non-
compliance. 
4. special training for those who work with psychiatric patients, minors, women and 
pregnant women is available. 
5. existing treatment policies and guidelines facilitate integration and linking of 
drug dependence and infectious services to guarantee evidence-based and 
accessible treatment for both conditions.  
6. treatment services are tailored to the needs of people with drug use disorders 
from minority groups, and cultural mediators and interpreters are available 
whenever necessary in order to minimize cultural and language barriers for 
minorities  
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Principle 6: ADDICTION TREATMENT AND THE CRIMINAL JUSTICE SYSTEM  
 
Description and Justification  
Drug related crimes are highly prevalent, and many people are incarcerated for drug 
related offences. These include offences to which a drug's pharmacologic effects 
contribute; offences motivated by the user's need for money to support continued 
use; and offences connected to drug distribution itself.  A significant proportion of 
people going through   criminal systems worldwide are drug dependent.  
 
In general, drug use should be seen as a health care condition and drug users 
should be treated in the health care system rather than in the criminal justice system 
where possible.   
 
Interventions for drug dependent people in the criminal justice system should 
address treatment as an alternative to incarceration, and also provide drug 
dependence treatment while in prison and after release. Effective coordination 
between the health/drug dependence treatment system and the criminal justice 
system is necessary to address the twin problems of drug use related crime and the 
treatment and care needs of drug dependent people.  
 
Research results indicate that drug dependence treatment is highly effective in 
reducing crime. Treatment and care as alternative to imprisonment or commenced in 
prison followed by support and social reintegration after release decrease the risk of 
relapse in drug use, of HIV transmission and of re-incidence in crime, with significant 
benefits for the individual health, as well as public security and social savings. 
Offering treatment as an alternative to incarceration is a highly cost-effective 
measure for society. 
 
Components  
 
 Diversion schemes from criminal justice system into treatment. Treatment as 
an alternative to imprisonment or other penal sanctions should be made 
available to drug dependent offenders. Such schemes bring people with drug 
dependence out of the criminal justice system into medical and rehabilitation 
programmes and allow drug treatment under a compulsory court order 
instead of penal sanctions. If treatment is discontinued, penal sanctions will 
be the consequence. In this way, treatment is offered as an alternative to 
incarceration or other penal sanctions, but not imposed without consent.  
 Human rights principles described in a separate section certainly apply to 
people charged with crimes related to illicit substances. Drug dependent 
people in prison have the right to receive the health care and treatment that 
are guaranteed in treatment centres in the community.  
 Human rights principles described in a separate section certainly apply to 
people charged with crimes related to illicit substances. This includes the right 
of addicted patients in prison setting to receive the health care and treatment 
that are guaranteed in treatment centres in the community. 
 Continuity of services. Specific interventions to reduce high-risk behaviour in 
regard to infectious diseases should be available in prison. If prisoners go into 
withdrawal, treatment should be initiated following good clinical practices.  For 
those inmates already in treatment before incarceration, medical treatment, 
especially pharmacological therapy, should not be discontinued when 
entering prison. Special facilities for pregnant women and mothers with small 
children are needed to provide for the best bonding circumstances. 
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  Psychosocial interventions, including vocational training can support 
reintegration after release. 
 Continuous care in the community upon release is crucial to meaningfully 
reintegrate drug dependent offenders into the community. Without access to 
education, job opportunities, housing, insurance, and health care including 
drug dependence treatment, persons in recovery face a higher risk of relapse 
and related mortality and also increase the burden on their communities.  
 Neither detention nor forced labor have been recognized by science as 
treatment for drug use disorders, 
  
Actions to promote this principle 
Ensure that: 
1. the legal framework allows the full implementation of drug 
dependence treatment and care options for offenders, in particular 
treatment as an alternative to incarceration and psychosocial and 
pharmacological treatment in prisons 
2. mechanisms to guarantee coordination between the criminal justice 
system and drug dependence treatment system are in place and 
operational. Such mechanisms and collaborative work will promote the 
implementation and monitoring of diversion schemes as an alternative 
to incarceration.   
3. drug using inmates are offered a range of treatment and care 
services, including prevention of transmission of blood-borne 
diseases, drug dependence pharmacological and psychosocial 
treatment, rehabilitation, preparation for release, and linkage to 
community services 
4. criminal justice and prison staff are made aware of the needs of drug 
dependent offenders and trained to support prevention and treatment 
interventions in prison settings. 
5. staff in charge of delivering drug dependence treatment (either health 
prison staff or external staff) are properly trained in the provision of 
evidence-based treatment and ethical standards, and show respectful, 
non-judgmental, and non-stigmatizing attitudes 
6. links and referrals to community agencies are established for 
continuation of the treatment for patients in the criminal justice system. 
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PRINCIPLE 7: COMMUNITY INVOLVEMENT, PARTICIPATION AND PATIENT 
ORIENTATION 
 
Description and Justification  
A community based response to drug use and dependence can support and 
encourage behavioural changes directly in the community. This might imply a 
paradigm shift from a directive to a more cooperative form of service delivery, for 
which the active involvement of local stakeholders (governmental and non-
governmental organizations, private sector, community leaders, religious 
organizations, and traditional healers), community members (families) and the target 
populations is needed to establish ownership and an integrated network of 
community-based health care services.  
 
Components  
 Patient active involvement aims to promote ownership and responsibility, 
change in individual behavior, and improvement of the quality and utilization 
of health services. 
 Accountability to the community. There is increasing recognition that the 
process of service development needs to be accountable to and shaped by 
the wide range of community interests. The community and service users play 
an important role in helping shape an approach that ensures appropriate 
accountability and responsibility of all those involved in the delivery of 
services 
 Community-oriented interventions can increase community support to people 
with drug problems and promote supportive public opinions and health policy. 
Community information and empowerment can also help reduce 
discrimination and social marginalization. De-stigmatization of affected 
individuals is substantial to improve accessibility to treatment and 
reintegration into society.  
 Mainstreaming drug dependence treatment in health and social care 
interventions not only enables the treatment of a larger number of patients, it 
also promotes a paradigm change within society to acknowledge drug 
dependence as a multi-factorial disorder.  
 Linkages. It is key to establish links between drug dependence treatment 
services and hospital services, such as emergency rooms, infectious 
diseases and internal medicine departments, as well as with specialized 
social services such as housing, vocational training and employment. 
Integrating psychiatric and drug dependence treatment increases retention of 
patients with co-morbid psychiatric disorders and reduces mortality.  
 NGOs can play a significant role in the provision of services for patients with 
drug dependence in coordination with the public health system. They can be 
particularly helpful in the process of scaling up treatment and facilitation of 
rehabilitation and reintegration. 
 
Action to promote this principle 
Ensure that: 
1. target populations, their families, community members and local 
organizations are actively involved in the planning, implementation and 
monitoring of drug dependence  treatment services 
2. services are integrated within the public health and social care networks, 
and establish links with all relevant partners in the community 
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 3. primary health, mental health, and social care service staff are trained in 
and conduct screening for drug use and drug use disorders, and deliver 
brief interventions 
4. services promote a close therapist-patient interpersonal relationship and a 
therapeutic alliance sharing the goals and methods of the program in 
advance and periodically collect patient feed-back on services provided 
5. services involve and support the families of the patients in the therapeutic 
process, as relevant, and provide support for family members. 
6. governmental and non-governmental organizations collaborate and are 
involved in establishing an integrated treatment network in the community.  
7. patients, families and community members are actively involved in 
improving the community drug problems and contribute to changing the 
public perception of drug dependence towards a chronic complex disease 
model. 
8. a sound and long-term educational and awareness strategy aimed at the 
general public is implemented to disseminate the concept of addiction as 
a disease and promote the value of evidence-based treatment.  
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 PRINCIPLE 8: CLINICAL GOVERNANCE OF DRUG DEPENDENCE TREATMENT 
SERVICES 
 
Description and Justification  
A drug dependence treatment service requires an accountable, efficient and effective 
method of clinical governance that facilitates the achievement of its goals.  
 
Service organization needs to reflect current research evidence and be responsive to 
service user needs.  Its policies, programmes, procedures and coordination 
mechanisms should be defined in advance and clarified to all therapeutic team 
members, administration, and target population.  
 
Components  
 Service policy and protocols clarify and facilitate a common understanding of 
the treatment programme’s philosophy, aims and objectives, strategic 
management, therapeutic approach, target population and programmes and 
procedures.  They critically provide details such as the staffing plan, human 
resource management and development, access and referral information and 
policies, physical environment, accommodation and food, and operational 
policies 
 Treatment protocols are written documents including details concerning 
procedures for assessment, care planning and provision of treatment. These 
include information on patient admission criteria, assessment, care planning 
and review, and treatment completition, as well as a clear statement of who 
will be involved in the different phases of treatment 
 Qualified staff: clear definition of staff members’ roles and responsibilities and 
appropriate continuing education are needed for the delivery of high quality 
services. Mechanisms for staff appraisal and career development, including 
orientation, education, training and time release to pursue further education 
are necessary to keep standards high.  
 Supervision and other forms of support are needed for the prevention of 
burnout among staff members. Each professional group will require specific 
training to work successfully with people with drug dependence disorder, and 
national policies can set the standards of ongoing education required in order 
standardize and certify the qualifications of drug dependence treatment 
professionals. The integration of drug dependence services into primary 
health care requires the introduction of adequate training on drug use 
disorders in general medicine curricula. In addition to undergraduate, 
graduate and postgraduate programs, teaching courses with e-learning 
modules can enhance further training for treatment professionals.  
 Financial resources. Sustainable sources of funding at adequate levels are 
needed to ensure an appropriate service delivery, and proper financial 
management and accountability mechanisms should be in place. Whenever 
possible, costs for staff education and for evaluation should be included in the 
relevant budget.  
 Communication structures and networking between drug dependence 
treatment services offering different programmes and with other relevant 
institutions such as general practitioners, specialists (e.g. psychiatrists, 
infection specialists, etc.) and  social services need to be established and 
keep operations for effective referral and continuum of care  
 Monitoring systems are a core element of a treatment service that wishes to 
understand how well it is serving the needs of its clients and provide 
evaluation and feedback on service and system performance for quality 
assessment. Record systems include information about patients, services 
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 delivered, human resources management, and payroll and should  guarantee 
client confidentiality 
 Updating services. The nature of drug use and related problems in a 
community will change over time, and in consequence services will need to 
adapt and reorient their programmes in order to respond to their clients’ 
evolving needs.  Services will also need to build on feed-back from patients, 
their relatives and the community, as well on  as monitoring and evaluation 
results with a view to improving their quality and performance  
 
Actions to promote this principle 
Ensure that: 
1. services meet quality standards required for accreditation with respect 
to organization, management and delivery of treatment  
2. written service policy and protocols are available, known to all staff 
and guide service delivery  
3. there are sufficient staff working at addiction treatment centres and 
that they are adequately qualified, and receive ongoing evidence-
based training, certification, support and supervision 
4. policies for staff selection, recruitment, employment and performance 
monitoring are clearly specified and known to all 
5. a sustainable source of funding is available at adequate levels and 
proper financial management and accountability mechanisms are in 
place  
6. drug dependence treatment services network and link with relevant 
generalist and specialized health and social services in order to 
provide a continuum of care to their patients    
7. monitoring systems provide evaluation and feedback on service and 
system performance for quality assurance.  
8. adequate record systems in place and that client confidentiality is 
maintained  
9. services are aware of drug use trends in the community and adapt 
their programmes to ensure that they continue to be responsive  
10. service programmes, rules and procedures are periodically revised on 
the basis of continuous feed-back, monitoring and evaluation 
processes 
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 PRINCIPLE 9: TREATMENT SYSTEMS: POLICY DEVELOPMENT, STRATEGIC PLANNING 
AND COORDINATION OF SERVICES 
 
Description and Justification  
A systematic approach to drug use disorders and patients in need of treatment, as 
well as to planning and implementation of services require a logical, step-by-step 
sequence that links policy to needs assessment and treatment planning and 
implementation, to monitoring and evaluation. 
Components  
 As a fundamental step, formulation of a treatment policy for drug use 
disorders by relevant authorities in governments is needed for the 
development of treatment systems and implementation of effective 
interventions.  A good treatment policy will be based on evidence of 
effectiveness and cost-effectiveness. Government policies set the tone for the 
development of drug addiction treatment and, in combination with political will, 
can produce significant improvements in treatment and care of people with 
drug use disorders.  Effective  policies are multisectoral, and define the role 
and responsibilities of all relevant partners, including health, welfare, labour, 
criminal justice, and civil society 
 Link to prevention. Treatment services and systems broaden their reach when 
developed alongside and connected to prevention interventions aiming at 
providing youth, adults and communities with the knowledge, skills and 
opportunities to avoid risky behaviors and choose healthy lifestyles. All these 
prevention interventions, including targeted interventions for populations that 
are at high-risk of drug use, are complementary to services for individuals that 
have started to use drugs. Linkages between prevention interventions and 
treatment services facilitate referrals of individuals who have started to use 
substances to appropriate ٛ counselling and treatment services.   
 Situation assessment. Understanding the types of people who may seek help, 
patterns of drug use and how they change over time in any one population, 
and the preferences for different types of treatment are important in effective 
drug dependence treatment planning.  
 Coordination between different sectors (health, social welfare, criminal 
justice) and appropriate balance between specialised services and primary 
care can produce best results.  Further, in a comprehensive treatment 
system, a variety of levels of service provision will be available.  
 Continuum of care. A good drug dependence treatment policy will outline the 
mechanisms for service coordination. Given the multiple physical, 
psychological and social needs of people with drug dependence, coordinated 
care across different health and welfare services is essential for smooth 
transition between modalities and services, achieving a continuum of care, 
and ultimately attaining positive clinical outcomes.   
 Mulltidisciplinary approach. Such comprehensive treatment system involves 
diverse professional groups including medical doctors/psychiatrists, nurses, 
psychologists, social workers, occupational therapists, and criminal justice 
workers (parole and probation officers, prison staff). NGOs play a very 
important role in many countries and it is important that their services are 
integrated within the overall treatment system.  
 Capacity building. Government and training institutions need to plan to ensure 
the availability of trained staff in the future. This may include integration of 
drug treatment into the curriculum in medical and nursing schools.    
 20
  Quality assurance, monitoring and evaluation. To ensure quality in the drug 
treatment network, a system of clinical governance should be developed with 
clear lines of clinical accountability, continuous monitoring of patient well 
being, adverse events and intermittent external evaluation.  
 
 
Actions to promote this principle 
Ensure that: 
1. policy documents describing the treatment system philosophy, 
objectives, approaches and funding, as well as the role and 
responsibilities of different partners are available and known to all 
relevant partners.  Information on the number, type, and distribution of 
services available and envisaged within the treatment system will be 
useful for planning and development purposes. 
2. links between drug use prevention, drug dependence treatment, and 
prevention of health and social consequences of drug use are 
established and operational 
3. treatment planning is based on estimates and descriptions of the 
nature and extent of the drug problem, as well as of the characteristics 
of the population in need  
4. the roles of the national, regional and local agencies in different 
sectors responsible for the  delivery of drug dependence treatment 
and rehabilitation are defined and mechanisms for effective 
coordination established 
5. a combination of primary care and specialized services for drug 
dependence people is available, as relevant to the needs of the 
affected population and local resources 
6. as far as possible, services are staffed by multidisciplinary teams 
including physicians/psychiatrist, nurses, psychologists, social 
workers, and other professionals 
7. mechanisms to delivery adequate initial training and ongoing 
development for professionals involved in treatment and rehabilitation 
are available 
8. quality standards for drug dependence treatment services are 
established and compliance is required for  accreditation, and 
mechanisms for clinical governance, monitoring and evaluation are 
identified 
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